In Brasília, a city already bearing the highest per-capita dengue burden in Brazil, the dead are disproportionately old — nearly three in ten fatalities in 2024 belong to those aged eighty and above. Across the country, dengue has claimed three thousand lives this year, more than triple the toll of the same period in 2023, and the disease follows an ancient logic: the older the body, the less it can resist. Yet the one vaccine approved to interrupt this logic was never tested on those who need it most, leaving the elderly in a silence that science itself created.
Metrópoles
· May 27, 2024
· health
· 4 min de leitura
High
Apuração: Verificado
Nearly 30% of DF dengue deaths are seniors over 80, vaccine unavailable for elderly
101 elderly residents aged 80+ died from dengue in DF during 2024; 365 total dengue deaths recorded in the capital.
◉
Health & Medicine
2834 artigos relacionados
Ozempic and GLP-1 drugs: how the weight-loss revolution works and what…
O GLOBO · 99% correspondência
Retatrutida achieves 30% weight loss in landmark obesity study
Veja Saúde · 90% correspondência
Anvisa aprova remdesivir contra covid-19 e registra vacina de Oxford
Jornal de Brasília · 90% correspondência
Brazil Gets New Blood Test for Early Alzheimer's Detection
Olhar Digital · 90% correspondência
Medical Expert Warns of Tirzepatide Risks, Emphasizes Need for Profess…
UNIPAR · 90% correspondência
Cobertura Relacionada
Folha de S.Paulo · Aug 26
Ônibus escolar cai em ribanceira e deixa duas crianças feridas em SC
Ônibus escolar com dez crianças caiu dez metros em ribanceira em Santa Catarina. Duas crianças ficaram feridas e foram h…
G1 · Aug 26 Incêndio em hospital do Paquistão mata ao menos 15 bebêsPelo menos 15 recém-nascidos morreram em incêndio no hospital PIMS em Islamabad, causado por falha no sistema de ar-cond…
G1 · Aug 26 Zelador agredido com paulada evolui na UTI, mas segue internado no DFZelador agredido há 15 dias por homem em situação de rua apresenta melhora clínica na UTI, respondendo a estímulos e com…
Google News · Aug 26 Diretor do Atlético-MG acusa Kaio Jorge de 'maldade e deslealdade' após lance polêmicoDirigente do Atlético-MG acusa Kaio Jorge de jogada maldosa e desleal que resultou em queda do zagueiro Ruan Tressoldi, …
Viés e Enquadramento
Não há dados de análise detalhada para esta lente. Tente executar as lentes novamente no painel de administração.
Impacto Geopolítico
🌎
Brazil's dengue crisis disproportionately kills elderly citizens (30% of DF deaths are 80+), but available vaccines exclude the most vulnerable population, creating a critical public health gap.
Escalation Risk
high
Confidence
HIGH
Brazil
Distrito Federal (Brasília)
Latin America
Exposes healthcare system fragmentation and regulatory gaps in Brazil's vaccine approval process. Highlights tension between pharmaceutical companies' liability concerns and public health needs in developing nations, potentially affecting Brazil's regional health leadership and WHO credibility.
Similar to 2016 Zika crisis in Brazil where vulnerable populations (pregnant women, infants) lacked adequate preventive options, revealing systemic weaknesses in emergency health response and vaccine equity.
Lente Econômica
📈
Dengue mortality crisis in Brazil's capital disproportionately affects elderly 80+, representing 27.6% of deaths, while available vaccines exclude this vulnerable population.
Market Signal
bearish
Confidence
HIGH
Healthcare and pharmaceuticals
Public health administration
Elderly care services
Insurance and social security
Elderly households face heightened health risks and mortality without vaccine protection; families bear increased caregiving costs and potential loss of income from elderly dependents; healthcare system strain increases out-of-pocket expenses for vulnerable populations.
Government must urgently expand vaccine approval for 80+ age group; potential regulatory review of vaccine licensing criteria; increased public health spending on dengue prevention and elderly care; possible litigation against pharmaceutical companies for age-based exclusions; pressure for expedited clinical trials in geriatric populations.